Goldman Sachs Group, Inc. (The) reaffirmed their sell rating on shares of AstraZeneca plc (LON:AZN) in a research report sent to investors on Friday. The firm currently has a GBX 3,900 ($50.93) price objective on the biopharmaceutical company’s stock.
A number of other equities analysts also recently weighed in on the company. Shore Capital restated a hold rating on shares of AstraZeneca plc in a research note on Thursday, July 13th. J P Morgan Chase & Co reaffirmed a neutral rating on shares of AstraZeneca plc in a report on Thursday, July 13th. Kepler Capital Markets reaffirmed a buy rating and issued a GBX 5,500 ($71.82) price target on shares of AstraZeneca plc in a report on Thursday, July 13th. Liberum Capital reaffirmed a buy rating and issued a GBX 5,500 ($71.82) price target on shares of AstraZeneca plc in a report on Thursday, July 13th. Finally, Citigroup Inc. reaffirmed a buy rating and issued a GBX 6,000 ($78.35) price target on shares of AstraZeneca plc in a report on Thursday, July 13th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of GBX 5,251.80 ($68.58).
AstraZeneca plc (LON AZN) traded up 0.58% during mid-day trading on Friday, reaching GBX 5069.00. The company had a trading volume of 1,763,249 shares. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00. The stock has a 50 day moving average price of GBX 5,259.89 and a 200 day moving average price of GBX 4,769.91. The company’s market capitalization is GBX 64.17 billion.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.